Citalopram-induced severe hyponatraemia with coma and seizure: Case report with literature and spontaneous reports review

Adverse Drug Reactions and Toxicological Reviews

Volumn 21, Issue 4, 2002, Pages 179-187

  Fisher, Alexander ^a   Davis, Michael ^a,b   Croft Baker, James ^a   Purcell, Patrick ^c   McLean, Allan ^a,d  

^a CANBERRA HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^d NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; NEFAZODONE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PSYCHOTROPIC AGENT; RAMIPRIL; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VENLAFAXINE;

COMA; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG OVERDOSE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; MUSCLE INJURY; POLYPHARMACY; PSYCHOSIS; REVIEW; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SODIUM BLOOD LEVEL;

POMACANTHUS MACULOSUS;

EID: 0036917164     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256195     Document Type: Review

References (59)

1. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967; 42 (5): 790-806
2. Luzecky MH, Burman KD, Schultz ER. The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration. South Med J 1974; 67 (4): 495-7
3. Ajlouni K, Kern MW, Tures JF, et al. Thiothixene-induced hyponatraemia. Arch Intern Med 1974: 134 (6): 1103-5
4. Australian Drug Reaction Advisory Committee. Selective serotonin reuptake inhibitors and SIADH. Med J Aust 1996; 164: 562
5. Liu BA, Mittmann N, Knowles SR, et al. Hyponatraemia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. CMAJ 1996; 155 (5): 519-27
6. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: Review and proposed mechanisms in the elderly. J Psychopharmacol 1998; 12 (4): 396-400
7. Spigset O, Hedenmalm K. Hyponatraemia in relation to treatment with antidepressants: A survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Pharmacotherapy 1997; 17 (2): 348-52
8. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: A retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002; 17 (3): 231-7
9. Wilkinson TJ, Begg EJ, Winter AC, et al. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol 1999; 47 (2): 211-7
10. Pillans PI, Coulter DM. Fluoxetine and hyponatraemia: A potential hazard in the elderly. N Z Med J 1994; 107 (973): 85-6
11. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998; 13 (1): 12-5
12. Strachan J, Shepherd J. Hyponatraemia associated with the use of selective serotonin re-uptake inhibitors. Aust N Z J Psychiatry 1998; 32 (2): 295-8
13. Voegeli J, Baumann P. Inappropriate secretion of antidiuretic hormone and SSRIs. Br J Psychiatry 1996; 169 (4): 524-5
14. Christensen O, Sorensen HA, Almdal TP. Adverse effects of selective serotonin uptake inhibitors: Hyponatraemia caused by Schwartz-Bartter syndrome. Ugeskr Laeger 1996; 158 (48): 6920-2
15. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 1997; 12 (1): 61-3
16. Pradalier A, Devars Du Mayne JF, Barzegar C, et al. Hyponatraemia and probable inappropriate secretion of antidiuretic hormone due to citalopram. Therapie 1998; 53 (6): 600-2
17. Riquelme A, Mendez F, Ortiz AM, et al. Severe and recent hyponatraemia and hypokalemia associated to the use of hydrochlorothiazide, enalapril and citalopram: Clinical case. Rev Med Chil 1999; 127 (10): 1223-8
18. Berrocal E, Esteban C, Delgado V, et al. The inappropriate antidiuretic hormone secretion syndrome and citalopram [letter]. Med Clin (Barc) 1999; 112 (2): 78
19. Christe C, Vogt N. SSRI-induced SIADH in older people. J Am Geriatr Soc 1999; 47 (5): 630-1
20. Zullino D, Brauchli S, Horvath A, et al. Inappropriate antidiuretic hormone secretion and rhabdomyolysis associated with citalopram. Therapie 2000; 55 (5): 651-2
21. Odeh M, Beny A, Oliven A. Severe symptomatic hyponatraemia during citalopram therapy. Am J Med Sci 2001; 321 (2): 159-60
22. Bourgeois JA, Babine SE, Bahadur N. A case of SIADH and hyponatraemia associated with citalopram. Psychosomatics 2002; 43 (3): 241-2
23. Siegler EL, Tamres D, Berlin JA, et al. Risk factors for the development of hyponatraemia in psychiatric inpatients. Arch Intern Med 1995; 155 (9): 953-7
24. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-45
25. Tilly-Gentric A. Severe hyponatraemia associated with ramipril therapy in an old woman. J Am Geriatr Soc 1995; 43 (12): 1448-9
26. Malaterre HR, Kallee K, Daver LM. Hyponatraemia and amlodipine therapy. Cardiovasc Drugs Ther 1999; 13 (2): 171-2
27. Van Der Klooster JM, Peters R, Ashruf RZ, et al. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion with convulsions, coma and pulmonary oedema in a patient using paroxetine. Neth J Med 1997; 51 (6): 237-9
28. Personne M, Sjoberg G, Persson H. Citalopram overdose: Review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35 (3): 237-40
29. Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacother 1997; 31 (1): 108-10
30. Kirby D, Ames D. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001; 16 (5): 484-93
31. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 1998; 12 (3): S5-20
32. Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999; 19 (6): 675-89
33. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram: A review of pharmacological and clinical effects. J Psychiatry Neurosci 2000; 25 (3): 241-54
34. Fredericson Overo K, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86 (3): 253-7
35. Miller M. Hyponatraemia: Age-related risk factors and therapy decisions. Geriatrics 1998; 53 (7): 32-42
36. Chan TY. Drug-induced syndrome of inappropriate antidiuretic hormone secretion: Causes, diagnosis and management. Drugs Aging 1997; 11 (1): 27-44
37. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatraemic encephalopathy in menstruant women. Ann Intern Med 1992; 117 (11): 891-7
38. Ayus JC, Arieff AI. Chronic hyponatraemic encephalopathy in postmenopausal women: Association of therapies with morbidity and mortality. JAMA 1999; 281 (24): 2299-304
39. Fonzo-Christe C, Vogt N. Susceptibility of the elderly patient to hyponatraemia induced by selective serotonin reuptake inhibitors. Therapie 2000; 55 (5): 597-604
40. Burke D, Franker S. Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Aust N Z J Psychiatry 1996; 30 (2): 295-8
41. Cohen BJ, Mahelsky M, Adler L. More cases of SIADH with fluoxetine. Am J Psychiatry 1990; 147 (7): 948-9.
42. Bell C, Anderson D. SSRI-induced hyponatraemia [letter]. Int J Geriatr Psychiatry 1998; 13 (2): 128
43. Jackson C, Carson W, Markowitz J, et al. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry 1995; 152 (5): 809-10
44. Flint AJ, Crosby J, Genik JL. Recurrent hyponatraemia associated with fluoxetine and paroxetine [letter]. Am J Psychiatry 1996; 153 (1): 134
45. Ayonrinde OT, Sanfilippo FM. SSRI antidepressants and SIADH. Aust N Z J Psychiatry 1997; 31 (2): 306-7.
46. Staab JP, Yerkes SA, Cheney EM, et al. Transient SIADH associated with fluoxetine. Am J Psychiatry 1990; 147 (11): 1569-70
47. Doshi D, Borison R. Association of transient SIADH with sertraline. Am J Psychiatry 1994; 151 (5): 779-80
48. Thornton SL, Resch DS. SIADH associated with sertraline therapy [letter]. Am J Psychiatry 1995; 152 (5): 809
49. Sawchenko PE, Swanson LW, Steinbusch HW, et al. The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res 1983; 277 (2): 355-60
50. Anderson IK, Martin GR, Ramage AG. Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats. Br J Pharmacol 1992; 107 (4): 1020-8.
51. Bagdy G, Sved AF, Murphy DL, et al. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol 1992; 210 (3): 285-9
52. Pergola PE, Sved AF, Voogt JL, et al. Effect of serotonin on vasopressin release: A comparison to corticosterone, prolactin and renin. Neuroendocrinology 1993; 57 (3): 550-8.
53. Saydoff JA, Rittenhouse PA, Carnes M, et al. Neuroendocrine and cardiovascular effects of serotonin: Selective role of brain angiotensin on vasopressin. Am J Physiol 1996; 270 (3 Pt 1): E513-21
54. Brownfield MS, Yracheta J, Chu F, et al. Functional chemical neuroanatomy of serotonergic neurons and their targets: Antibody production and immunohistochemistry (IHC) for 5-HT, its precursor (5-HTP) and metabolite (5-HIAA), biosynthetic enzyme (TPH), transporter (SERT), and three receptors (5-HT2A, 5-HT5a, 5-HT7). Ann N Y Acad Sci 1998; 861: 232-3.
55. Leibowitz SF, Eidelman D, Suh JS, et al. Mapping study of noradrenergic stimulation of vasopressin release. Exp Neurol 1990; 110 (3): 298-305
56. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983; 280 (1): 176-9
57. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11 (4): 275-83
58. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32: Suppl. 1: 1-21
59. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance. Pharmacol Toxicol 1996; 78 (4): 203-8